The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old.

Sanofi SNY announced that the European Commission (EC) has approved its fully-liquid meningococcal vaccine MenQuadfi for the active immunization of individuals, aged 12 months and above against ...

(RTTNews) - Sanofi said that the U.S. Food and Drug Administration has approved a Biologics License Application for MenQuadfi Meningococcal Conjugate Vaccine for the prevention of invasive ...

Sanofi (SNY) wins FDA label expansion for its MenQuadfi meningococcal vaccine for use in infants as young as six weeks. Read more here.

DUBLIN, June 15, 2020 /PRNewswire/ -- The "MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) Drug Overview" report has been added to ResearchAndMarkets.com's offering ...

US regulators have issued a green light for Sanofi’s meningococcal vaccine MenQuadfi for the prevention of invasive meningococcal disease in persons two years of age and older. “Meningococcal ...

(RTTNews) - French pharma major Sanofi (SNYNF, SNY) announced Thursday that the U.S. Food and Drug Administration has accepted for review the Biologics License Application or BLA for MenQuadfi, a ...

Sanofi SNY announced that the European Commission (EC) has approved its fully-liquid meningococcal vaccine MenQuadfi for the active immunization of individuals, aged 12 months and above against ...

MenQuadfi (Sanofi Pasteur) is the first FDA-approved quadrivalent meningococcal vaccine that uses tetanus toxoid as a protein carrier, the release said.

Sanofi SNY announced that the European Commission (EC) has approved its fully-liquid meningococcal vaccine MenQuadfi for the active immunization of individuals, aged 12 months and above against ...